Content area
Full Text
Staten Biotechnology has exercised an exclusive option to license ARGX-116 (STT-5058), an anti-ApoC3 SIMPLE Antibody from argenx N.V.
Staten has unique expertise in dyslipidemia and collaborated with argenx to develop an antibody-based treatment for dyslipidemia since 2015, targeting ApoC3, which is involved in hypertriglyceridemia and forms a component of highly atherogenic lipoproteins. Targeting ApoC3 is expected to reduce circulating triglycerides and remnant lipoproteins that are the cause of the residual cardiovascular mortality in patients treated with statins. Staten has advanced the program into the preclinical stage and is preparing to initiate the first-in-man study.
ApoC3 is known to inhibit the activity of...